Arecor has developed Arestat™, a formulation technology, which enables the formulation of labile proteins and vaccines as stable aqueous formulations even at high concentrations or in the presence of ionising radiation.

As a simple reformulation, the technology can be readily integrated into existing manufacturing processes. Arestat™ does not involve the covalent modification of biologics and uses only GRAS (Generally Regarded As Safe) excipients approved by relevant regulatory authorities.

Arecor is collaborating with a number of pharmaceutical and biotech companies to develop recombinant proteins and vaccines for application in drugs, medical devices or diagnostics.

Arestat™ has a proven track record and has been incorporated into a Class III medical device (Oxyzyme™) approved in the EU and Canada. It is currently being applied to several recombinant biologics in various stages of development for administration via parenteral, ocular and transdermal routes.